Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxcyte Inc PCVX

Healthcare Biotechnology
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation... see more

Recent & Breaking News (NDAQ:PCVX)

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire January 30, 2024

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

GlobeNewswire January 29, 2024

Vaxcyte Appoints Whitney Jones as Chief People Officer

GlobeNewswire January 16, 2024

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

GlobeNewswire January 4, 2024

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

GlobeNewswire December 4, 2023

Vaxcyte Appoints Jacks Lee to Board of Directors

GlobeNewswire November 28, 2023

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

GlobeNewswire November 27, 2023

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

GlobeNewswire November 9, 2023

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 6, 2023

Vaxcyte to Present at Upcoming Investor Conferences

GlobeNewswire October 31, 2023

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

GlobeNewswire October 19, 2023

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

GlobeNewswire October 16, 2023

Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 19, 2023

Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 8, 2023

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

GlobeNewswire July 11, 2023

Vaxcyte to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 8, 2023

Vaxcyte to Present at the BofA Securities 2023 Health Care Conference

GlobeNewswire May 3, 2023

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire April 21, 2023

Vaxcyte Announces Pricing of $500 Million Public Offering

GlobeNewswire April 19, 2023